1. 155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT. (December 2022) Authors: Klinghammer, K.; Saba, N.F.; Castelluci, E.; Colevas, A.D.; Rutkowski, T.; Greil, R.; Thurner, D.; Müller-Richter, U.; Di Giacomo, A.M.; Grewal, J.; Ottensmeier, C.H.H.; Atasoy, A.; Shpyro, S.; Brück, P.; Dias, J.; Ganser, C.; Türeci, Ö.; Sahin, U. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗